Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (251-260 of 471) with videos related to

Pageof 48
Sort By:
European Journal of Heart Failure|February 16, 2019
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trialJoão Pedro Ferreira, Paula Abreu, John J V McMurray, et al.
Circulation|December 7, 2005
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon, Nagesh Anavekar, Hicham Skali, et al.
European Journal of Heart Failure|January 30, 2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Nathaniel M Hawkins, Zhen Huang, Karen S Pieper, et al.
American Heart Journal|June 7, 2011
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trialsPeter S Pang, Mihai Gheorghiade, Jamil Dihu, et al.
American Heart Journal|November 19, 2011
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programCono A Ariti, John G F Cleland, Stuart J Pocock, et al.
European Journal of Heart Failure|June 1, 2005
Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)Andrea Di Lenarda, Willem J Remme, Andrew Charlesworth, et al.
European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.
European Journal of Heart Failure|July 4, 2015
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)Jane A Cannon, Timothy J Collier, Li Shen, et al.
JACC. Heart Failure|January 10, 2016
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF TrialOrly Vardeny, Brian Claggett, Jacob A Udell, et al.
European Journal of Heart Failure|February 12, 2019
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
Pageof 48

Showing results (251-260 of 471) with videos related to

Sort By:
Pageof 48
European Journal of Heart Failure|February 16, 2019
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trialJoão Pedro Ferreira, Paula Abreu, John J V McMurray, et al.
Circulation|December 7, 2005
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon, Nagesh Anavekar, Hicham Skali, et al.
European Journal of Heart Failure|January 30, 2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Nathaniel M Hawkins, Zhen Huang, Karen S Pieper, et al.
American Heart Journal|June 7, 2011
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trialsPeter S Pang, Mihai Gheorghiade, Jamil Dihu, et al.
American Heart Journal|November 19, 2011
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programCono A Ariti, John G F Cleland, Stuart J Pocock, et al.
European Journal of Heart Failure|June 1, 2005
Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)Andrea Di Lenarda, Willem J Remme, Andrew Charlesworth, et al.
European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.
European Journal of Heart Failure|July 4, 2015
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)Jane A Cannon, Timothy J Collier, Li Shen, et al.
JACC. Heart Failure|January 10, 2016
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF TrialOrly Vardeny, Brian Claggett, Jacob A Udell, et al.
European Journal of Heart Failure|February 12, 2019
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
Pageof 48